Hungarian Brain Research Program(KTIA_NAP_13-2-2015-0001)
(MTA-SE-NAP B Genetic Brain Imaging Migraine Research Group)
(TKP2021-EGA-25)
Thematic Institutional Excellence Programme(TKP2021-EGA-24) Támogató: Emberi Erőforrások
Minisztériuma
(2019-2.1.7-ERA-NET-2020-00005) Támogató: Nemzeti Kutatási, Fejlesztési és Innovációs
Hivatal
ERA PerMed(ERAPERMED2019-108)
(ÚNKP-21-3-I-SE-32)
Szakterületek:
Gyógyszerészet, farmakogenomika, gyógyszerkutatás és tervezés, gyógyszeres kezelés
Altered tryptophan (TRP) metabolism may have an important role in migraine susceptibility
through its main metabolites, serotonin and kynurenine (KYN). Both affect pain processing
and stress response by interfering with neural and brain hypersensitivity and by interacting
with chemokines and cytokines that control vascular and inflammatory processes. The
involvement of these pathways in migraine has been widely studied, but acute citalopram
neuroendocrine challenge on TRP metabolism and cytokine profile has not been investigated
yet. In our study, females with episodic migraine without aura and healthy controls
were studied before and after acute citalopram or placebo in a double-blind setting.
At baseline, increased TRP/large neutral amino acid (LNAA) ratio and decreased RANTES
chemokine concentration were detected in migraine patients compared to controls. The
challenge induced a significant increase in TRP, KYN, and TRP/LNAA in healthy controls,
but not in migraine patients. Furthermore, migraine attack frequency negatively correlated
with KYN/TRP ratio and positively correlated with the neuroendocrine-challenge-induced
KYN concentration increase. Our results support a decreased breakdown of TRP via KYN
pathway and a failure to modulate TRP–KYN pathway during citalopram-induced acute
stress together with an increased vascular sensitivity in migraine. These mechanisms
may provide useful drug targets for future drug development.